You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
AstraZeneca
McKesson
McKinsey
Dow

Last Updated: August 14, 2020

DrugPatentWatch Database Preview

AVASTIN Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for AVASTIN

Identify potential brand extensions & biosimilar entrants

SponsorPhase
MedSIRPhase 2
Elizabeth BuchbinderPhase 2
Vascular Biogenics Ltd. operating as VBL TherapeuticsPhase 2

See all AVASTIN clinical trials

Recent Litigation for AVASTIN

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Genentech, Inc. v. Samsung Bioepis Co. Ltd.2020-06-28
Ravgen, Inc. v. Natera, Inc.2020-06-01
Ravgen, Inc. v. PerkinElmer Inc.2020-06-01

See all AVASTIN litigation

PTAB Litigation
PetitionerDate
2018-01-08
2018-01-05
2017-12-20

See all AVASTIN litigation

Company Disclosures: US Patents for AVASTIN

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial Athena Neurosciences, Inc. (South San Francisco, CA) 2014-01-25 RX Orphan company
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial Biogen, Inc. (Cambridge, MA) 2020-08-05 RX Orphan company
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial Athena Neurosciences, Inc. (South San Francisco, CA) 2014-01-25 RX Orphan company
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial Biogen, Inc. (Cambridge, MA) 2020-08-05 RX Orphan company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for AVASTIN

These patents were identified by searching patent claims

Supplementary Protection Certificates for AVASTIN

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
122015000061 Germany   Start Trial PRODUCT NAME: TRASTUZUMAB UND RECOMBINANTE HUMANE HYALURONIDASE; REGISTRATION NO/DATE: EU/1/00/145/002 20130826
93138 Luxembourg   Start Trial PRODUCT NAME: RITUXIMAB ET HYALURONIDASE HUMAINE RECOMBINANTE; FIRST REGISTRATION DATE: 20140326
300673 Netherlands   Start Trial PRODUCT NAME: PACLITAXEL, GEFORMULEERD ALS ALBUMINE-GEBONDEN NANODEELTJES; REGISTRATION NO/DATE: EU/1/07/428/001-002 20131220
132014902271575 Italy   Start Trial PRODUCT NAME: PACLITAXEL LEGATO ALL'ALBUMINA FORMULATO IN NANOPARTICELLE(ABRAXANE); AUTHORISATION NUMBER(S) AND DATE(S): EU/01/07/428, 20131220
122006000043 Germany   Start Trial PRODUCT NAME: NATALIZUMAB; NAT. REGISTRATION NO/DATE: EU /1/06/346/001 20060627; FIRST REGISTRATION: EU EU/1/06/346/001 20060627
92642 Luxembourg   Start Trial PRODUCT NAME: POMALIDOMIDE ET SES SELS, SOLVATES, HYDRATES OU STEREOISOMERES PHARMACEUTIQUEMENT ACCEPTABLES QUI EN DERIVENT (IMNOVID); FIRST REGISTRATION DATE: 20130805
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Harvard Business School
Mallinckrodt
Colorcon
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.